Post Profile

MEK inhibition in KRAS-mutant NSCLC did not improve survival

(European Society for Medical Oncology) MEK inhibitor selumetinib in combination with docetaxel does not improve progression free or overall survival in individuals with KRAS-mutant non-small-cell lung cancer (NSCLC), according to data presented at the ESMO 2016 Congress in Copenhagen.
read more


Related Posts

Hispanic/Latino Non-Small Cell Lung Cancer Patients Have Higher Overall Survival Than Non-Hispanic White Patients

Health : Medical News Today

Analysis of non-small cell lung cancer (NSCLC) patient records in the California Cancer Registry (CCR) database during the 20-year period of 1988-2008 indicates that Hispanics/Latinos with NSCLC have a higher overall survival compar...

Combining RNA Interference With Tyrosine Kinase Inhibitors Or Cetuximab Enhances Lung Cancer Therapy

Health : Medical News Today

Non-small cell lung cancer (NSCLC), the most common form of lung cancer, is usually treated with surgery and chemotherapy. However, a small group of patients can also be helped by treatment with tyrosine kinase inhibitors (TKI). New...

As Monotherapy And In Combinations, Ganetespib Showed Activity In KRAS-Mutant NSCLC

Health : Medical News Today

The investigational drug ganetespib, a synthetic second-generation Hsp90 inhibitor, slowed the growth of cancer cells taken from non-small cell lung cancer tumors with a mutation in the KRAS gene. The drug was even more active when ...

Medical News Today: Study finds drug improves survival for patients with non-small cell lung cancer

Health : Medical News Today

A new phase 3 trial finds that overall survival is longer for patient with non-small cell lung cancer treated with the drug nivolumab compared with chemotherapy drug docetaxel.

Significant survival gains with atezolizumab vs docetaxel for non-small-cell lung cancer

Health : EurekAlert: Health

(European Society for Medical Oncology) The first phase III study of PD-L1 inhibitor atezolizumab in previously-treated non-small-cell lung cancer has seen significant improvements in survival compared to standard chemotherapy, rese...


Copyright © 2016 Regator, LLC